{"doi":"10.1016/j.ajt.2024.02.013","title":"Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma","abstract":"Melanoma causes significant morbidity in solid organ transplant recipients (SOTRs). Melanomas diagnosed before transplantation can recur with intensive immunosuppression, but outcomes have not been well studied. We evaluated 901 non-Hispanic White SOTRs with a pretransplant melanoma identified using linked transplant and cancer registry data in the United States. Most pretransplant melanomas were invasive (60.7%), and the median time from diagnosis to transplantation was 5.1 years. After transplantation, 41 SOTRs developed a new invasive melanoma, corresponding to 9-fold increased risk compared with the general population (standardized incidence ratio, 9.2; 95% confidence interval [CI], 6.6-12). Twenty-two SOTRs died from melanoma after transplantation, corresponding to 52-fold increased risk (standardized mortality ratio, 52; 95% CI, 33-79). Risk factors for posttransplant melanoma included age at transplantation (adjusted hazard ratio [HR], 2.86; 95% CI, 1.24-6.60; for age 55+ vs <55 years) and maintenance immunosuppression with cyclosporine/azathioprine (adjusted HR, 2.53; 95% CI, 1.08-5.90). Melanoma mortality was strongly elevated after a posttransplant melanoma diagnosis (HR, 35.6; 95% CI, 14.0-90.4; adjusted for cyclosporine/azathioprine maintenance therapy and calendar year of transplantation). In conclusion, SOTRs with a pretransplant melanoma are at risk of adverse melanoma-related outcomes after transplantation. These findings support thorough dermatologic evaluation prior to transplantation and frequent posttransplant surveillance.","journal":"American Journal of Transplantation","year":2024,"id":449960,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":4,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9502,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":369161,"name":"Michael R. Sargen","orcid":"0000-0003-1039-2522","position":1,"is_corresponding":false},{"id":978854,"name":"April A. Austin","orcid":"0000-0002-8229-8589","position":2,"is_corresponding":false},{"id":404801,"name":"Mei‐Chin Hsieh","orcid":"0000-0001-7842-1225","position":3,"is_corresponding":false},{"id":390438,"name":"Karen Pawlish","orcid":"0000-0001-9019-8804","position":4,"is_corresponding":false},{"id":390439,"name":"Jie Li","orcid":"0009-0003-2774-9193","position":5,"is_corresponding":false},{"id":353157,"name":"Charles F. Lynch","orcid":"0000-0002-9542-6439","position":6,"is_corresponding":false},{"id":317483,"name":"Kelly J. Yu","orcid":"0000-0003-3832-6586","position":7,"is_corresponding":false},{"id":282491,"name":"Eric A. Engels","orcid":"0000-0003-0203-6958","position":8,"is_corresponding":false},{"id":1269746,"name":"Fiona O. Zwald","orcid":"0000-0002-4278-5171","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:02:20.585759Z","pmid":"38387619","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}